References

Maria Kleppe, Kaitlyn Shank, Papalexi Efthymia, Hugh Y. Riehnhoff, Ross L. Levine Lysine-Specific Histone Demethylase, LSD1, (KDM1A) As a Novel Therapeutic Target in Myeloproliferative NeoplasmsBlood Dec 2015, 126 (23) 601

Ly P. Vu, Luisa Luciani, Stephen D. Nimer. “Histone-modifying enzymes: their role in the pathogenesis of acute leukemia and their therapeutic potential” International Journal of Hematology, Volume 97, Issue 2, February 2013, pp 198-209 http://dx.doi.org/10.1007/s12185-012-1247-y

William J. Harris, Xu Huang, James T. Lynch, Gary J. Spencer, James R. Hitchin, Yaoyong Li, Filippo Ciceri, Julian G. Blaser, Brigit F. Greystoke, Allan M. Jordan, Crispin J. Miller, Donald J. Ogilvie, Tim C.P. Somervaille, “The Histone Demethylase KDM1A Sustains the Oncogenic Potential of MLL-AF9 Leukemia Stem Cells” Cancer Cell, Volume 21, Issue 4, 17 April 2012, pp 473-487 doi: http://dx.doi.org/10.1016/j.ccr.2012.03.014

Alyson A. Lokken, Nancy J. Zeleznik-Le “Breaking the LSD1/KDM1A Addiction: Therapeutic Targeting of the Epigenetic Modifier in AML” Cancer Cell, Volume 21, Issue 4, 17 April 2012, pp 451-453 http://dx.doi.org/10.1016/j.ccr.2012.03.027

Danielle Simmons, “Epigenetic Influences and Disease.” Nature Education 1(1):6, 2008 http://www.nature.com/scitable/topicpage/epigenetic-influences-and-disease-895#